2seventy Bio agrees to be acquired by Bristol Myers Squibb for $5.00/share, stock up

From Nasdaq: 2025-03-10 22:33:25

2seventy bio Inc. has agreed to be acquired by Bristol Myers Squibb for $5.00 per share in an all-cash deal, totaling approximately $286 million. This represents an 88% premium to the closing price on March 7, 2025. The Board of Directors recommends stockholders tender their shares. The transaction is expected to close in the second quarter of 2025, after which 2seventy bio’s common stock will no longer be listed on Nasdaq. Certain stockholders owning 5.3% of the outstanding shares have agreed to tender all their shares. TSVT stock closed at $2.80, up 5.26% in regular trading and gained 3.56% in after-hours trading.



Read more at Nasdaq: 2seventy Bio Agrees To Be Acquired By Bristol Myers Squibb For $5.00/shr; Stock Up